777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Regeneron Enters Sixth Amendment to License and Collaboration Agreement
Supplemental Information Regarding Award Rationale, Design Process, and Key Terms
Financial Results, Press Release
Regeneron Pharmaceuticals Reports $127 Million IPR&D Charge for Q2 2026
2026 Annual Meeting Results - Directors Elected at Regeneron Pharmaceuticals
Reports First Quarter 2026 Financial and Operating Results
Annual Report to Security Holders
Earnings Release
Q2
Q1
FY 2024
Q3
FY 2023
S-3ASR
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Additional Proxy Soliciting Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Annual Report of Proxy Voting Record
Submission Upload
Correspondence